Peptide · Vial
Verified recordBPC 157
$9010mg
An experimental peptide best known for early research into tissue repair, tendon injury and wound response.
Current batchBPC 004-012
Published result99.2% reported purity
EternaGen / TESA 003-040Peptide · Research use only
Tesamorelin
$110CAD
A synthetic peptide that mimics a natural signal involved in the release of growth hormone.
Currently unavailable
Select strength
1
Can’t find the right record?Send support the product name or batch code.
Contact supportProduct information
Tesamorelin, clearly explained.
A synthetic peptide that mimics a natural signal involved in the release of growth hormone.
Overview
Tesamorelin has meaningful human research, but it is tied to specific prescription formulations and adults with HIV-associated lipodystrophy. A research material is not interchangeable with an approved medicine.
Tesamorelin is a stabilized analogue of growth-hormone-releasing hormone. Authorized tesamorelin drug products have formulation-specific labelling for a defined population; a research material is not interchangeable with an approved medicine.- Format
- Vial
- Available strengths
- 10mg
- Batch
- TESA 003-040
- Purity
- 99.4%
Research at a glanceEstablished human evidence for a narrow, authorized drug indication
Reviewed 23 July 2026View research context Specifications
Product details
- Sequence / identity
- 44-amino-acid GHRH analogue
- Molecular formula
- Confirm in batch record
- Molecular weight
- 5135.9 g/mol
- Storage and handling
- Store according to the conditions printed on the vial and supplied Certificate of Analysis.
Batch documentationVerified record available
Review the analytical record connected to this exact batch.
- Batch
- TESA 003-040
- Purity
- 99.4%
Important research-use boundary
Tesamorelin has authorized prescription-drug formulations for a specific indication. This catalogue item is a separate research material and is not represented as an approved, substitutable or patient-ready medicine.
Explore the research
What has been studied?
Keep the context attached
Check what was studied, what researchers observed, and the limitation attached to each finding.
Question 01
HIV-associated lipodystrophy
Randomized trials studied adults living with HIV who had excess abdominal fat while receiving antiretroviral therapy.
Evidence so far: Phase 3 human evidenceQuestion 02
Visceral and liver fat
Additional trials in people living with HIV examined visceral adipose tissue and hepatic fat under defined protocols.
Evidence so far: Clinical research in a narrow populationQuestion 03
Not general weight management
Approved U.S. labelling states that tesamorelin is not indicated for weight-loss management and that formulations are not substitutable.
Evidence so far: Regulatory label boundaryProposed mechanism
How researchers are investigating the mechanism.
Tesamorelin stimulates pituitary growth-hormone release and increases downstream IGF-I. Clinical programmes measured visceral adipose tissue and metabolic or safety outcomes in carefully defined populations.
Study records
What was studied—and what was not.
See what researchers tested, what they observed and the limitation attached to each result.
Study 01Randomized 12-month trial in 404 adults living with HIV and excess abdominal fat
- What researchers saw
- The study reported a reduction in visceral adipose tissue during active treatment, with loss of the observed effect after switching to placebo.
- Why that is not the whole story
- The result applies to the trial intervention and population, not general fat loss or a research vial.
Study 02Current U.S. prescribing information for EGRIFTA WR
- What researchers saw
- The label describes one authorized indication and explicitly distinguishes non-substitutable formulations.
- Why that is not the whole story
- An EternaGen research material is not EGRIFTA WR and is not represented as an approved drug.
Evidence gaps
What remains unknown?
- Results should not be generalized to people without the studied HIV-associated condition.
- Long-term cardiovascular safety remains a labelled limitation of use.
- Identity, formulation and regulatory status must be verified independently; a shared compound name is not equivalence.
Primary sources
Check the original sources.
- Primary phase 3 studyFalutz et al. Tesamorelin in HIV-associated abdominal fat accumulation. JAIDS. 2010. PMID 20101189.
- Current regulatory labelU.S. FDA. EGRIFTA WR prescribing information. 2025.
- Canadian authorization recordHealth Canada Drug Product Database. EGRIFTA (tesamorelin), prescription product.
Related products
Continue comparing.
Peptide · Vial
Verified recordGHK-CU
From CA$5550mg100mg
A naturally occurring copper-binding peptide explored in skin, collagen and wound-healing research.
Current batchGHK 006-031
Published result99.5% reported purity
Peptide · Pen
Verified recordMOTS-c
From CA$20010mg40mg
A peptide made inside mitochondria and studied for its connection to energy, exercise and metabolic stress.
Current batchMOTS 005-021
Published result99.0% reported purity